Literature DB >> 30948373

Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research.

A Lasocki1,2, F Gaillard3,4.   

Abstract

There is a growing understanding of the prognostic importance of non-contrast-enhancing tumor in glioblastoma, and recent attempts at more aggressive management of this component using neurosurgical resection and radiosurgery have been shown to prolong survival. Optimizing these therapeutic strategies requires an understanding of the features that can distinguish non-contrast-enhancing tumor from other processes, in particular vasogenic edema; however, the limited and heterogeneous manner in which it has been defined in the literature limits clinical translation. This review covers pertinent literature on our growing understanding of non-contrast-enhancing tumor and focuses on key conventional MR imaging features for improving its delineation. Such features include subtle differences in the degree of FLAIR hyperintensity, gray matter involvement, and focal mass effect. Improved delineation of tumor from edema will facilitate more aggressive management of this component and potentially realize associated survival benefits.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2019        PMID: 30948373      PMCID: PMC7053910          DOI: 10.3174/ajnr.A6025

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  58 in total

1.  Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.

Authors:  Federico Pessina; Pierina Navarria; Luca Cozzi; Anna Maria Ascolese; Matteo Simonelli; Armando Santoro; Elena Clerici; Marco Rossi; Marta Scorsetti; Lorenzo Bello
Journal:  J Neurooncol       Date:  2017-07-08       Impact factor: 4.130

2.  Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

Authors:  Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Jeffrey M Rogg; Ronald L Wolf; Suyash Mohan; Helga Marques; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

3.  Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article.

Authors:  Yordanka N Yordanova; Sylvie Moritz-Gasser; Hugues Duffau
Journal:  J Neurosurg       Date:  2011-05-06       Impact factor: 5.115

4.  Correlation of myo-inositol levels and grading of cerebral astrocytomas.

Authors:  M Castillo; J K Smith; L Kwock
Journal:  AJNR Am J Neuroradiol       Date:  2000-10       Impact factor: 3.825

5.  Differential diagnosis by unenhanced FLAIR T2-weighted magnetic resonance images between solitary high grade gliomas and cerebral metastases appearing as contrast-enhancing cortico-subcortical lesions.

Authors:  Carmine Franco Muccio; Annachiara Tarantino; Gennaro Esposito; Alfonso Cerase
Journal:  J Neurooncol       Date:  2010-11-11       Impact factor: 4.130

6.  Multicentric/multifocal cerebral lesions: can fluid-attenuated inversion recovery aid the differentiation between glioma and metastases?

Authors:  S L Stuckey; R Wijedeera
Journal:  J Med Imaging Radiat Oncol       Date:  2008-04       Impact factor: 1.735

7.  Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.

Authors:  Arian Lasocki; Frank Gaillard; Mark Tacey; Katharine Drummond; Stephen Stuckey
Journal:  J Clin Neurosci       Date:  2017-10-05       Impact factor: 1.961

8.  Intraoperative image guidance in neurosurgery: development, current indications, and future trends.

Authors:  Chris Schulz; Stephan Waldeck; Uwe Max Mauer
Journal:  Radiol Res Pract       Date:  2012-05-08

9.  An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas.

Authors:  Martha Nowosielski; Matthew D DiFranco; Daniel Putzer; Marcel Seiz; Wolfgang Recheis; Andreas H Jacobs; Günther Stockhammer; Markus Hutterer
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

10.  Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas.

Authors:  Anne L Baldock; Sunyoung Ahn; Russell Rockne; Sandra Johnston; Maxwell Neal; David Corwin; Kamala Clark-Swanson; Greg Sterin; Andrew D Trister; Hani Malone; Victoria Ebiana; Adam M Sonabend; Maciej Mrugala; Jason K Rockhill; Daniel L Silbergeld; Albert Lai; Timothy Cloughesy; Guy M McKhann; Jeffrey N Bruce; Robert C Rostomily; Peter Canoll; Kristin R Swanson
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

View more
  29 in total

Review 1.  Neuro-Oncology and Radiogenomics: Time to Integrate?

Authors:  A Lasocki; M A Rosenthal; S J Roberts-Thomson; A Neal; K J Drummond
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

Review 2.  Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques.

Authors:  D J Leao; P G Craig; L F Godoy; C C Leite; B Policeni
Journal:  AJNR Am J Neuroradiol       Date:  2019-12-19       Impact factor: 3.825

3.  Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.

Authors:  Arian Lasocki; Michael E Buckland; Katharine J Drummond; Heng Wei; Jing Xie; Michael Christie; Andrew Neal; Frank Gaillard
Journal:  Neuroradiology       Date:  2022-05-24       Impact factor: 2.804

4.  Radio-Pathomic Maps of Cell Density Identify Brain Tumor Invasion beyond Traditional MRI-Defined Margins.

Authors:  S A Bobholz; A K Lowman; M Brehler; F Kyereme; S R Duenweg; J Sherman; S D McGarry; E J Cochran; J Connelly; W M Mueller; M Agarwal; A Banerjee; P S LaViolette
Journal:  AJNR Am J Neuroradiol       Date:  2022-04-14       Impact factor: 3.825

5.  MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features.

Authors:  H J Choi; S H Choi; S-H You; R-E Yoo; K M Kang; T J Yun; J-H Kim; C-H Sohn; C-K Park; S-H Park
Journal:  AJNR Am J Neuroradiol       Date:  2021-02-25       Impact factor: 3.825

6.  Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.

Authors:  Sohil H Patel; Prem P Batchala; Thomas J Eluvathingal Muttikkal; Sergio S Ferrante; James T Patrie; Camilo E Fadul; David Schiff; M Beatriz Lopes; Rajan Jain
Journal:  J Neurooncol       Date:  2021-03-04       Impact factor: 4.130

7.  Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.

Authors:  Stuart A Grossman; Carlos G Romo; Michelle A Rudek; Jeffrey Supko; Joy Fisher; L Burt Nabors; Patrick Y Wen; David M Peereboom; Benjamin M Ellingson; William Elmquist; Fred G Barker; David Kamson; Jann N Sarkaria; William Timmer; Ranjit S Bindra; Xiaobu Ye
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

8.  Feasibility of glioblastoma tissue response mapping with physiologic BOLD imaging using precise oxygen and carbon dioxide challenge.

Authors:  Vittorio Stumpo; Martina Sebök; Christiaan Hendrik Bas van Niftrik; Katharina Seystahl; Nicolin Hainc; Zsolt Kulcsar; Michael Weller; Luca Regli; Jorn Fierstra
Journal:  MAGMA       Date:  2021-12-07       Impact factor: 2.310

9.  Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.

Authors:  Hiroyuki Tatekawa; Hiroyuki Uetani; Akifumi Hagiwara; Shadfar Bahri; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson
Journal:  Ann Nucl Med       Date:  2021-06-14       Impact factor: 2.668

10.  Predictive Role of the Apparent Diffusion Coefficient and MRI Morphologic Features on IDH Status in Patients With Diffuse Glioma: A Retrospective Cross-Sectional Study.

Authors:  Jun Zhang; Hong Peng; Yu-Lin Wang; Hua-Feng Xiao; Yuan-Yuan Cui; Xiang-Bing Bian; De-Kang Zhang; Lin Ma
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.